Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)

SON-1410 (IL18-FHAB-IL12), a bispecific combination of Interleukins 18 and 12, was selected based on data generated in a mouse melanoma study comparing three bispecific constructsSelection of the asset was performed with input from Sonnet's …